Nightstar Therapeutics PLC Completion of Acquisition by Biogen
June 07, 2019 05:44 ET
|
Nightstar Therapeutics
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen
June 05, 2019 08:33 ET
|
Nightstar Therapeutics
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen
May 29, 2019 09:00 ET
|
Nightstar Therapeutics
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019
May 08, 2019 09:36 ET
|
Nightstar Therapeutics
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Nightstar Shareholders Vote “FOR” Proposed Acquisition by Biogen
April 26, 2019 02:00 ET
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar") (NASDAQ: NITE) today announced that both leading independent proxy advisory firms,...
Nightstar Therapeutics plc Announcement of Expiry of HSR Waiting Period and Satisfaction of Antitrust Condition
April 16, 2019 08:35 ET
|
Nightstar Therapeutics
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
Recommended Acquisition of Nightstar Therapeutics plc by Tungsten Bidco Limited, a Wholly-Owned Subsidiary of Biogen Switzerland Holdings GmbH; Posting of Scheme Document
April 09, 2019 08:55 ET
|
Nightstar Therapeutics
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR...
Nightstar Therapeutics plc reaches agreement to be acquired by Biogen
March 04, 2019 02:01 ET
|
Nightstar Therapeutics
Biogen to acquire Nightstar for US$ 25.50 per share in cashTransaction expected to be completed by mid-year 2019 WALTHAM, Mass. and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Nightstar Therapeutics...
Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results
November 13, 2018 01:00 ET
|
Nightstar Therapeutics
Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy Data from Phase 2/3...
Nightstar Therapeutics to Participate in Multiple Conferences in November
November 08, 2018 06:05 ET
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...